{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:50:41Z","timestamp":1790128241767,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011851","name":"Fight against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Foundation Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.esmoop.2026.107693","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:21:53Z","timestamp":1778275313000},"page":"107693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4785-8891","authenticated-orcid":false,"given":"S.","family":"Joris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Collignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3051-6481","authenticated-orcid":false,"given":"M.","family":"Rasschaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.T.","family":"de Roodenbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5429-7888","authenticated-orcid":false,"given":"F.P.","family":"Duhoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Canon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-8643","authenticated-orcid":false,"given":"S.","family":"Tejpar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mebis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7563-0179","authenticated-orcid":false,"given":"L.","family":"Decoster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9946-4726","authenticated-orcid":false,"given":"P.","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2389-0742","authenticated-orcid":false,"given":"J.","family":"De Gr\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.esmoop.2026.107693_bib1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/cancers17050801","article-title":"Tumor-agnostic therapies in practice: challenges, innovations, and future perspectives","volume":"17","author":"Wu","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107693_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107693_bib3","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107693_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"9737","key":"10.1016\/j.esmoop.2026.107693_bib5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.esmoop.2026.107693_bib6","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107693_bib7","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107693_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.107693_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","article-title":"OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"184","author":"Robson","year":"2023","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107693_bib10","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107693_bib11","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.euo.2024.09.013","volume":"8","author":"Clarke","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2026.107693_bib12","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.esmoop.2026.107693_bib13","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.21.01604","article-title":"Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107693_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.esmoop.2026.107693_bib15","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"issue":"44","key":"10.1016\/j.esmoop.2026.107693_bib16","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107693_bib17","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41467-017-00921-w","article-title":"Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes","volume":"8","author":"Riaz","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107693_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100524","article-title":"PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment","volume":"7","author":"Thouvenin","year":"2022","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107693_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102041","article-title":"Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study","volume":"8","author":"Joris","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.107693_bib20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2340\/1651-226X.2025.43374","article-title":"Complete remission with olaparib in BRIP1-mutated metastatic high-grade pleomorphic sarcoma: case study and literature review\u2014an example of a genomic profiling-based tumor treatment, in a cancer type with high unmet clinical need","volume":"64","author":"Thooft","year":"2025","journal-title":"Acta Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107693_bib21","article-title":"Phase 2 study of olaparib in malignant mesothelioma and correlation of efficacy with germline or somatic mutations in BAP1 gene","volume":"2","author":"Ghafoor","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.esmoop.2026.107693_bib22","article-title":"Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway-deficient neoplasms","volume":"8","author":"George","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107693_bib23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.annonc.2023.01.012","article-title":"Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation","volume":"34","author":"Kwapisz","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107693_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/mc.23829","article-title":"Functional analysis of BARD1 missense variants on homology-directed repair in ovarian and breast cancers","volume":"64","author":"Li","year":"2025","journal-title":"Mol Carcinog"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107693_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/bco2.455","article-title":"PARP inhibitor-based treatment in metastatic, castration-resistant prostate cancer (mCRPC): a systematic review and meta-analysis","volume":"6","author":"Roberto","year":"2025","journal-title":"BJUI Compass"},{"issue":"7776","key":"10.1016\/j.esmoop.2026.107693_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","article-title":"The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs","volume":"574","author":"van der Velden","year":"2019","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.esmoop.2026.107693_bib27","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1016\/j.cell.2025.05.046","article-title":"Functional assessment of all ATM SNVs using prime editing and deep learning","volume":"188","author":"Lee","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2026.107693_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","article-title":"Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","volume":"3","author":"Marquard","year":"2015","journal-title":"Biomark Res"},{"issue":"25","key":"10.1016\/j.esmoop.2026.107693_bib29","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.esmoop.2026.107693_bib30","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.107693_bib31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00292-024-01381-y","article-title":"Leveraging homologous recombination deficiency for sarcoma: unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma","volume":"45","author":"Planas-Paz","year":"2024","journal-title":"Pathologie (Heidelb)"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:13:06Z","timestamp":1780290786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926016352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2059702926016352"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107693","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107693"}}